Iparomlimab and Tuvonralimab in HNSCC

NCT07090317 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Iparomlimab and Tuvonralimab

Sponsor

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University